Brian Jonas, MD
Enriched profileChief, Division of Malignant Hematology, Cellular Therapy and Transplantation; Professor of Medicine · UC Davis Comprehensive Cancer Center
Brian Jonas is Chief, Division of Malignant Hematology, Cellular Therapy and Transplantation; Professor of Medicine at UC Davis Comprehensive Cancer Center. OpenAlex indexes 288 publications with 10,355 citations (h-index 36); ClinicalTrials.gov lists 15 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 24 Oct 2026
Brian Jonas, M.D., PHD, is Chief, Division of Malignant Hematology, Cellular Therapy and Transplantation at UC Davis Comprehensive Cancer Center / University of California Davis Medical Center. The public record shows 288 publications with 10,355 citations (h-index 36), centered on Acute Myeloid Leukemia Research, Retinoids in leukemia and cellular processes, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 13 companies, 1 NIH-funded awards (2023–2026).
- Most recent indexed publication: 2026 · Leukemia & lymphoma
- Top research focus: Acute Myeloid Leukemia Research
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 24 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 39 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 96.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 24 Oct 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
Sponsor: Aspera Biomedicines, Inc.
- CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Sponsor: CERo Therapeutics Holdings, Inc.
Industry payments
Updated 24 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- Daiichi Sankyo Inc.Program year20251 payment
- ABBVIE INC.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
56.4%Kinase inhibitor28.6%Sprycel23%Iclusig22%Imatinib Mesylate17%Bosulif11%Jakafi10%Imbruvica9%Tasigna9%Part D<11 patientsBCL-2 Inhibitor11.1%Venclexta100%Part D≥12 patients+ 5 more classes in this area
Dermatology
18.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18.2%Acyclovir100%Part D≥25 patientsAnti-infectives
14.8%Fluoroquinolone Antibacterial5.5%Levofloxacin100%Part D≥13 patientsTriazole and tetrazole derivatives4.4%Cresemba100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 24 Oct 2026
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
Congress activity
Updated 24 Oct 2026
96 congress contributions (2015–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- A phase 2 study of olutasidenib in combination with azacitidine followed by olutasidenib maintenance after venetoclax plus a hypomethylating agent regimen for IDH1 -mutated acute myeloid leukemia (University of California Hematologic Malignancies Consortium Study 2441).
ASCO Annual Meeting
ASCO2026Presenting author - Association of acute myeloid leukemia (AML) patient, disease, and molecular characteristics with a long-term (LT) response to olutasidenib.
ASCO Annual Meeting
ASCO2026Co-author - A phase 2 study of olutasidenib in relapsed/refractory acute myeloid leukemia: Outcomes by number of prior treatment regimens.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 24 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.
Blood advances
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaArticle2,885 citations2020
- 02
- 03
- 04
- 05
Network
Updated 24 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 24 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/brian-jonas-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
health.ucdavis.edu/medical-center/team/11638/brian-jonas---leukemia---bone-marrow-transplant-sacramento
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗ - Other
healthtree.org/aml/community/directory/CA/uc-davis-comprehensive-cancer-center-sacramento-ca/brian-jonas
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗ - Other
thedoctorschannel.com
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →thedoctorschannel.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 24 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →education.binaytara.org ↗
Editorial & leadership roles
journal and society appointments- Chair
Hematologic Malignancies Disease Team, UC Davis Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗ - Chair
Data and Safety Monitoring Committee, UC Davis Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗ - Member
NCCN Myelodysplastic Syndromes Panel
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗ - Member
NCCN AML and ALL Panels
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
Media & interviews
press, podcasts and appearances- Faculty Chair
AML Clinical Case Series on The Doctor's Channel
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thedoctorschannel.com ↗ - Presenter
Applying Evolving Targeted Therapy in Acute Myeloid Leukemia educational program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →freecme.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
David Gandara, MD
UC Davis Comprehensive Cancer Center
Jonathan Riess, MD
UC Davis Comprehensive Cancer Center
Richard Valicenti, MD
UC Davis Comprehensive Cancer Center
Jeanna Welborn, MD
UC Davis Comprehensive Cancer Center
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center